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Abstract
Overexpression of the basement membrane protein Laminin c2 (Lamc2) is a feature of many epidermal and oral dysplasias
and all invasive squamous cell carcinomas (SCCs). This abnormality has potential value as an immunohistochemical
biomarker of premalignancy but its mechanism has remained unknown. We recently reported that Lamc2 overexpression in
culture is the result of deregulated translation controls and depends on the MAPK-RSK signaling cascade. Here we identify
eIF4B as the RSK downstream effector responsible for elevated Lamc2 as well as MYC protein in neoplastic epithelial cells.
Premalignant dysplastic keratinocytes, SCC cells, and keratinocytes expressing the E6 oncoprotein of human papillomavirus
(HPV) type 16 displayed MAPK-RSK and mTOR-S6K1 activation and overexpressed Lamc2 and MYC in culture.
Immunohistochemical staining of oral dysplasias and SCCs for distinct, RSK- and S6K1-specific S6 phosphorylation events
revealed that their respective upstream pathways become hyperactive at the same time during neoplastic progression.
However, pharmacologic kinase inhibitor studies in culture revealed that Lamc2 and MYC overexpression depends on
MAPK-RSK activity, independent of PI3K-mTOR-S6K1. eIF4B knockdown reduced Lamc2 and MYC protein expression,
consistent with the known requirement for eIF4B to translate mRNAs with long, complex 59 untranslated regions (59-UTRs).
Accordingly, expression of a luciferase reporter construct preceded by the Lamc2 59-UTR proved to be RSK-dependent and
mTOR-independent. These results demonstrate that RSK activation of eIF4B is causally linked to elevated Lamc2 and MYC
protein levels during neoplastic progression to invasive SCC. These findings have potential clinical significance for
identifying premalignant lesions and for developing targeted drugs to treat SCC.
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Introduction
Squamous cell carcinoma (SCC) is an aggressive cancer that
arises from stratified epithelia, including the epidermis and the
bronchial, cervical, and oral epithelia. Oral SCC is a significant
health problem, with 27,000 new diagnoses and 5,500 deaths per
year in the U.S. alone [1]. Genetic alterations frequently present in
advanced oral and oropharyngeal SCCs include mutations of
TP53, CDKN2A, HRAS, PTEN, and PIK3CA and gene amplifica-
tion of EGFR and MYC [2,3]. Many of these alterations result in
activation of the MAPK pathway (i.e., RAS-RAF-MEK-RSK) or
the PI3K-AKT-mTOR pathway, or both [2–5]. The major
carcinogenic factors contributing to acquisition of these genetic
changes are tobacco mutagens. However, 6% of oral and a higher
proportion of oropharyngeal SCCs involve infection with high-risk
HPV types 16 or 18 and integration and expression of their E6
and E7 viral oncogenes [6–8], the activities of which can replace
mutations in some of the genes listed above to confer neoplastic
properties.
Deeply invasive or regionally metastatic oral SCC cannot be
surgically resected and is refractory to cure by conventional
chemotherapy, targeted kinase inhibitor, or blocking antibody
approaches [9–11]. Identification of early, premalignant stages
that are completely resectable should greatly increase cure rate.
Oral SCCs usually develop from visually identifiable, dysplastic
precursor lesions. Such dysplasias have an incidence rate of ,1–
3% in adults [12]; however the majority never progress to invasive
SCC and current conventional histopathologic criteria cannot
predict which lesions will progress [12–15]. Thus, there is an
urgent need both to identify predictive biomarkers for evaluating
dysplasias and to better understand the mechanisms of neoplastic
progression in order to reveal potential drug targets for therapy.
Abnormal overexpression of the Lamc2 subunit of the
stratified epithelial basement membrane protein Laminin-332 is
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a characteristic of many types of invasive carcinoma [16–18] and
is already present in many preinvasive dysplasias of the oral
epithelium and epidermis [19,20]. We recently described a culture
system that recapitulates the absence of Lamc2 expression by
normal epithelium and the abnormal Lamc2 overexpression by
premalignant dysplasias and SCCs in vivo [21]. In this system,
normal human keratinocytes cease Lamc2 synthesis as they
become confluent whereas premalignant keratinocytes, SCC cells,
and keratinocytes expressing the HPV16 E6 oncoprotein continue
synthesizing Lamc2. EGFR/MAPK/RSK hyperactivity, detect-
able in culture and in vivo by RSK-specific phosphorylation of
ribosomal protein S6 at its S235 residue, proved to be essential for
driving Lamc2 overexpression. Additionally, Lamc2 overexpres-
sion correlated closely with RSK-mediated phosphorylation of the
translation regulatory factor eIF4B [21]. Activated eIF4B is a
cofactor for eIF4A, an RNA helicase that is required to unwind the
long, stem-looped 59-UTRs of certain mRNAs, such as those of
MYC, ODC, and BCL2, to expose the AUG translation initiation
codon [22–26].
Here we characterize the molecular basis of Lamc2 overex-
pression and of the MYC overexpression that invariably accom-
panies it in SCC cells, premalignant keratinocytes, and keratino-
cytes expressing the HPV16 E6 viral oncoprotein. Using specific
antibodies that detect and distinguish MAPK/RSK from mTOR/
S6K1-dependent phosphorylation events on S6, we find concur-
rent hyperactivation of both pathways during epithelial neoplastic
progression in vivo, presaging Lamc2 overexpression. Using genetic
and pharmacologic inhibitor approaches in culture, we find that
RSK activation of eIF4B, independent of PI3K/mTOR, is critical
for Lamc2 protein expression and that the Lamc2 mRNA 59-
UTR sequence is responsible for this regulatory mechanism.
Materials and Methods
Cells and Cell Culture
Human cell lines used in this study were the premalignant
dysplastic oral keratinocyte line POE9n [27,28]; the epidermal
SCC cell line SCC-13 [29] and the oral SCC cell line SCC-68
[21]; the normal epidermal keratinocyte primary line Strain N
[29,30]; and N/E6(JH26) [21], a derivative of strain N engineered
by retroviral transduction to express the JH26 mutant form of the
E6 oncoprotein of HPV16 [31,32]. All of these cell lines were
derived in the Rheinwald lab and cultures for experiments were
initiated from archival frozen stocks in the Rheinwald lab’s
collection. Their derivation and use in this study were approved by
the Brigham and Women’s Hospital’s Human Studies IRB.
Cells were cultured in keratinocyte serum-free medium (Ksfm)
(GIBCO/Life Technologies, Carlsbad, CA), +25 mg/ml bovine
pituitary extract +0.2 ng/ml epidermal growth factor (EGF)
+0.4 mM CaCl2 +penicillin/streptomycin (pen/strep) (GIBCO/
Life Technologies) [27]. To keep cells healthy and metabolically
active at high density, after reaching ,40% confluence cultures
were fed daily with ‘‘1:1 medium’’ (1:1 (vol:vol) Ca2+-free DMEM
(GIBCO/Life Technologies): Ksfm +25 mg/ml bovine pituitary
extract +0.2 ng/ml epidermal growth factor (EGF) +0.1 mM
CaCl2, +pen/strep, as described [21]. This lower calcium medium
prevented stratification and accumulation of suprabasal, termi-
nally differentiated cells, the percentages of which could vary
among cell lines and treatment conditions. Thus, in this medium
only the relevant basal cell populations of cell lines and treatment
conditions were analyzed.
HEK293T cells [33] (Broad Institute, Cambridge, MA), used
for lentivirus production, were grown in DMEM +10% newborn
bovine calf serum (Hyclone/Thermo Scientific, Rockford, IL) +
pen/strep.
Small molecule kinase inhibitors
The EGFR inhibitor gefitinib [34,35] (provided by Pasi Janne,
Dana-Farber Cancer Institute, Boston, MA) was used at 1 mM, the
RSK inhibitor BI-D1870 [36] (Symanis Limited, Auckland, NZ) at
2.5 mM, the MEK inhibitor U0126 [37] (Cell Signaling Technol-
ogy) at 5 mM, the mTORC1/2 inhibitor Ku-0063794 [38,39]
(Chemdea, Ridgewood, NJ) at 500 nM, the mTORC1 inhibitor
rapamycin (Cell Signaling Technology) at 10 nM, and the PI3K
p110a subunit inhibitor PIK-75 [40] (Selleckchem, Houston, TX)
at 40 nM. Inhibitors were added to the medium from 1,000X
concentrated solutions in DMSO, stored frozen between uses.
Antibodies
Murine monoclonal antibodies used were: Laminin c2 (clone
D4B5 [41], Chemicon, Billerica MA), Laminin b3 (clone 17, BD
Transduction Laboratories, Franklin Lakes, NJ). Rabbit mono-
clonal antibodies used were: MYC (cloneY69, Epitomics,
Burlingame, CA), and phospho- (p-)S6(S235/236) (clone 91B2),
p-S6(S240/244) (clone D68F8), p-AKT(S473), all from Cell
Signaling Technology (Danvers, MA). Rabbit polyclonal antibod-
ies used were: b-actin (A-2066, SIGMA-Aldrich); p-eIF4B(S442)
(AbCam, Cambridge, MA), p-RSK(S380) (clone AF889) (R&D
Systems, Minneapolis, MN); and ERK1/2, p-ERK1/2(T202/
Y204), and eIF4B (all from Cell Signaling Technology).
Western blot analysis
Cultures were lysed in reducing Laemmli SDS sample buffer,
separated by SDS-PAGE on 4–20% gradient gels (Bio-Rad,
Hercules, CA), blotted to polyvinyldifluoride membranes (Bio-
Rad), incubated primary and with peroxidase-conjugated anti-
bodies, treated with chemiluminescence reagent, and exposed to
HyBlot CL film (Denville Scientific, Metuchen, NJ), as described
[21]. Blots were analyzed densitometrically using ImageJ software
version 1.45 (NIH, Bethesda, MD; http://rsbweb.nih.gov/ij). Two
different film exposures of each blot were analyzed. Band densities
of each sample were normalized to the density of the actin band of
the same sample and compared to the densities of control lanes in
the same film exposure.
Tissue samples and immunohistochemistry
Ten formalin-fixed, paraffin-embedded, lateral tongue tissue
specimens from the U. Conn. Oral Pathology archival collection
used in this study were obtained with written informed consent for
their use in research by the donors and analyzed anonymously
with the approval of the Brigham and Women’s Hospital Human
Studies IRB. H&E stained slides of these specimens were evaluated
by one of us (EN) who is an oral pathologist and included normal
epithelium, dysplasias, and invasive SCC. Sequential 5 mm
paraffin sections (not baked at 50uC after sectioning to preserve
the Lamc2 antigen [19]) were immunostained by the avidin/
biotin/peroxidase complex method and Vector Red as the color
reagent (Vectastain Elite ABC kit, Vector Laboratories, Burlin-
game, CA), examined using a NIKON Eclipse TE2000-S
microscope, and photographed with a SPOT Insight QE camera,
as described [21]. Immunostained slides were quantified for%
basal layer p-S6(S235), p-S6(S240), and Lamc2 as follows: the total
length in section of the dysplastic area of each specimen was
measured in the H&E-stained slide and the percentage of the
dysplastic region with p-S6 positive and Lamc2 positive basal cells
was determined.
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Bicistronic luciferase constructs and reporter assays
The pDL-N bicistronic Renilla/Firefly luciferase reporter
plasmid [42] was used for translation reporter assays. Translation
initiation of the Renilla luciferase cistron is 59 cap-dependent, and
translation initiation of the Firefly luciferase cistron is independent
of 59 cap- or other eIF4-dependent mechanisms because it is
preceded by the hepatitis C virus internal ribosomal entry site
(IRES). The 59-UTRs of the LAMC2 gene (encoding Lam2) and of
the ODC gene (encoding ornithine decarboxylase) were cloned into
pDL-N upstream of the Renilla AUG translation initiation site.
The pDL-N/(ODC 59UTR) plasmid was provided by Drs. Nina
Ilic and Tom Roberts, Dana-Farber Cancer Institute. We
generated the pDL-N/(Lamc2 59UTR) plasmid by PCR-ampli-
fying the 314 bp Lamc2 59UTR sequence from genomic DNA
isolated from cultured human keratinocytes using the primer pairs:
FWD: AGAAGCTTCTTGGCCCGGGCCAGGTGTGC, and
REV: AGAAGCTTGGCGGGGCCGGGCCGCTCAGT, con-
taining HindIII sites (underlined above), and cloning into the
HindIII site upstream of the Renilla translation initiation site in
pDN-L.
SCC-13 cells were transfected in 24-well plates in quadruplicate
using 50 ng of the luciferase reporter plasmids and linear
polyethylenimine 25kDa (PEI-25K; Polysciences, Inc., Warring-
ton, PA) as transfection reagent. Cells were lysed 2 d post-
transfection in 100 ml passive lysis buffer (dual luciferase reporter
kit, Promega, Madison, WI) per well. Extracts were assayed using
a dual luciferase system (Promega) and measured in a GLOMAX
96 microplate luminometer (Promega). When used, kinase
inhibitors were added 1 d after transfection and the cells lysed
1d thereafter. Fold-change in activity was calculated as the ratio of
Renilla and Firefly luciferase activities in pDL-N/(59-UTR)
construct-transfected cells compared to the ratio in pDL-N-
transfected cells. Standard error of the mean was calculated from
results of four experiments, each performed in quadruplicate.
Student’s t test was calculated to determine statistical significance
of differences.
Quantitative PCR
Total RNA was isolated from cells using the RNeasy Plus Mini
Kit (Qiagen, Valencia, CA) and cDNA synthesized from 500 ng
total RNA using the iScript cDNA synthesis kit (Bio-Rad). mRNA
levels were measured by quantitative real-time PCR (qPCR) using
FAST SYBR-Green PCR Master Mix (Applied Biosystems, Foster
City, CA) on an ABI StepONE Plus Instrument (40 cycles of 95uC
for 15 s and 58uC for 30 s). Amplicons used were: Laminin c2
(gene name: LAMC2) (FWD: 5-CTCTGCTTCTCGCTCCTCC-
39, and REV: 59-TCTGTGAAGTTCCCGATCAA-39); MYC
(MYC) (FWD: 59-TTTCGGGTAGTGGAAAACCA-39, and
REV: 59-CACCGAGTCGTAGTCGAGGT-39); eIF4B (EIF4B)
(FWD: 59-TTTCCCTCTCCCAACATGG-39, and REV: 59-
GTGCTTCCTCCACCAGTACC-39); GAPDH (GAPDH) (FWD:
59-GAGCCTCAAGATCATCAGCA-39, and REV: 59-ACAG-
TCTTCTGGGTGGCAGT-39). Relative expression was calcu-
lated using the DDCt method, normalizing values to GAPDH
within each sample, and calculating standard error of the mean
from the results of triplicate aliquots.
Lentiviral shRNA and expression vectors and
transduction
Three short hairpin sequences designed to target specifically
mRNAs encoding human eIF4B (shEIF4B) and a control hairpin
targeting Luciferase (shLUC) in the pLKO.1 lentiviral backbone
were obtained from the RNAi Consortium (TRC Broad Institute,
Cambridge, MA). The eIF4B shRNA vectors targeted the
following sequences in eIF4B mRNA:
Clone #1: 59-GCGGAGAAACACCTTGATCTT-39,
Clone #3: 59-CCAACTTCTAAACCTCCCAAA-39,
Clone #4: 59-CTACCCTATGATGTTACAGAA-39.
To produce lentiviral supernatants, HEK293T cells in 6-wells
were transfected with 1 mg of shRNA vector plasmid, 1 mg
pCMV-GagPol(psPAX2)D8.9, and 100 ng pCMV-VSVG, using
PEI-25K as transfection reagent. Lentiviral supernatants were
collected in 1:1 medium 48 h and 72 h after transfection, passed
through 0.45 mm pore filters, and stored at 280uC before use.
Cells plated 1 d previously at 105 cells/9 cm2 well in Ksfm were
transduced for 6–7 h with lentiviral supernatants containing 2 mg/
ml polybrene (SIGMA) as described [30]. Transduced cells were
subcultured the next day into Ksfm +1 mg/ml puromycin and
selected for 3 d to obtain pure transductant populations.
Results
Lamc2 and MYC overexpression and eIF4B
phosphorylation are EGFR/MAPK-dependent but PI3K/
mTOR/S6K1 -independent
To extend our previous finding that Lamc2 and MYC
overexpression correlated with MAPK pathway hyperactivity in
SCC cells [21], we investigated more thoroughly the possibility of
a role for the PI3K/mTOR pathway. To this end, we examined
the effects on Lamc2 and MYC expression of PIK-75, an inhibitor
of the PI3K subunit p110a [40], and of rapamycin, a specific
inhibitor of mTORC1, comparing these to gefitinib, an inhibitor
of EGFR kinase that can stimulate both the MAPK and PI3K
signaling cascades (Fig. 1A).
As predicted [21], gefitinib reduced Lamc2 and MYC
expression, associated with reduced levels of p-ERK, p-RSK, p-
S6(S235), and p-eIF4B (Fig. 1B). Neither PIK-75 nor rapamycin
reduced Lamc2 and MYC expression and p-ERK, p-RSK, and p-
eIF4B levels were unaltered by these inhibitors. The activities of
PIK-75 and rapamycin in this system were demonstrated by the
reduction of p-AKT levels by PIK-75 and of p-S6(S240) levels by
rapamycin. Notably, PIK-75 did not affect p-S6(S240) levels
(Fig. 1B). Considering that our culture conditions do not impose
nutrient or growth factor limitations which otherwise might
instigate AMPK activation of TSC1/2 (Fig. 1A), it is not
unexpected that cells were independent of PI3K/AKT-dependent
activation of mTORC1 and its downstream target S6K1.
The great reduction of p-S6(S235) levels by gefitinib and of p-
S6(S240) by rapamycin (Fig. 1B) support the conclusion that these
sites are phosphorylated by RSK and S6K1, respectively. On the
other hand, rapamycin inhibition of mTORC1 and consequently
inactive S6K1 also markedly reduced p-S6(S235) levels, despite
RSK remaining active as evidenced by the maintenance of p-
eIF4B levels in the presence of rapamycin (Fig. 1B). These results
are consistent with the conclusion that phosphorylation of
S6(S240) by S6K1 is an essential prerequisite for subsequent
phosphorylation of S6(S235) by RSK.
In vivo phosphorylation status of S6 as
immunohistochemical markers of MAPK and mTOR
activation
Our recent studies identified regions in oral epithelial and
vulvar epidermal SCCs and dysplasias that contained immuno-
histochemically-detectable p-S6(S235) in cells of the basal layer
[21,43]. The RSK- and S6K1-specific phosphorylations of S6 we
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found by Western blotting in cultured SCC cells (Fig. 1B) provided
the rationale for using p-S6(S235)- and p-S6(S240)-specific
antibodies on pathology tissue sections to detect activation of
(MAPK/RSK + mTORC1/S6K1) vs. activation of mTORC1/
S6K1 alone. We asked whether an event causing mTORC1/
S6K1 activation precedes an event causing MAPK/RSK activa-
tion during epithelial neoplastic progression. If so, this would be
manifested as an immunostaining pattern in which p-S6(S235)
positive cells always lie within a larger field of p-S6(S240) positive
cells.
To answer this question, we immunostained 10 human oral
dysplasia specimens, some of which also contained regions of
normal epithelium and SCC. Normal lateral tongue epithelium
present in these specimens always was Lamc2 negative and p-
S6(S240) and p-S6(S235) were confined to the suprabasal cell
layers (Fig. 2A). In areas of dysplasia, basal layer p-S6(S240) and p-
S6(S235) immunostaining always corresponded exactly, as dis-
cussed below. Proportions of the dysplastic regions positive for
basal layer p-S6 and Lamc2 ranged from 0–100% and 0–83%,
respectively/ When Lamc2 was detected in dysplasias and SCCs,
it was confined to cells within p-S6(S235) and p-S6(240) positive
regions, although not all p-S6 positive cells were Lamc2 positive
(Fig. 2B and Table 1), consistent with our previous studies [21,43].
(Note that two MYC antibodies that worked in Western blotting
and in immunofluorescence of methanol-fixed cultured cells failed
to detect this protein in tissue sections, precluding analysis of this
protein.)
The immunostaining intensity (and therefore the apparent level
of S6 phosphorylation) as well as the proportion of cells detectably
positive for p-S6 and Lamc2 varied among dysplasias (e.g.,
Fig. 2B,C) (Table 1). Some variability among specimens with
respect to immunostaining intensity and continuity could result
from different lengths of time before biopsy fixation or of time in
fixative before paraffin embedding. Intracellular p-S6 levels may
fluctuate more rapidly than that of Lamc2 protein, the latter
which requires 12 hr or more to pass through the endoplasmic
reticulum and Golgi and then vacate cells by secretion [21]. Our
results are consistent with the conclusion that the degree of
MAPK/RSK activation needed to stimulate Lamc2 overexpres-
sion is greater than that required to produce immunologically
detectable levels of p-S6(S235).
As expected from our cell culture finding that phosphorylation
of S6 at its S240 is a prerequisite for the p-S6(S235) event, regions
of dysplasias and SCCs that were basal layer p-S6(S235) positive
also were positive for p-S6(S240) (Fig. 2B-D). Our cell culture
studies (see Fig. 1B and below) disclosed that both MAPK and
mTOR pathways were hyperactive in SCC cells and premalignant
keratinocytes. We found no regions of dysplasias or SCCs that
were basal layer p-S6(S240) positive but p-S6(235) negative. Thus,
we did not detect an early stage of progression in which an event
activating the mTOR pathway precedes a separate event
activating the MAPK pathway. We concluded from these results
that a single event during neoplastic progression activates both an
element of the MAPK pathway upstream of RSK and an element
of the mTORC1 pathway upstream of S6K1.
Activation of eIF4B and Lamc2 mRNA translation are
both MAPK/RSK-dependent but mTOR/S6K1-
independent
We next examined SCC cells and premalignant dysplasia-
derived keratinocytes more closely for their MAPK and mTOR
signaling pathway activity and dependence on these pathways for
Lamc2 and MYC protein overexpression. We compared confluent
cultures of SCC-68 and of the premalignant oral keratinocyte line
POE9n. Untreated cultures were compared with replicate cultures
treated for 24 hr with inhibitors blocking various kinases in the
signal pathways described in Fig. 1A. Western blot analysis
Figure 1. Effects of inhibiting MAPK vs. PI3K/mTOR pathway
kinases on Lamc2 and MYC expression. A) Elements of the EGFR/
RAS/RAF/MEK/RSK (blue) and PI3K/AKT/mTOR (red) kinase cascade
signaling pathways and their downstream targets eIF4B and S6. Arrows
indicate that the upstream protein activates the downstream target,
whereas lines terminating in a crossbar indicate that the upstream
protein inhibits the downstream target. Kinase inhibitors are in blue
font. Proteins examined for their phosphorylation states by Western
blotting are underlined. B) Western blot of confluent cultures of SCC-68
treated for 24 hr with the EGFR kinase inhibitor gefitinib, the mTORC1
inhibitor rapamycin, or the PI3 kinase p110a-specific inhibitor PIK-75.
Densitometric analysis of the Lamc2 (black bars) and p-eIF4B (gray bars)
bands of each lane is shown in the bar graph below the blot. Lamc2
and p-eIF4B levels were normalized to the actin level in each lane and
then levels of Lamc2 and p-eIF4B in inhibitor-treated cultures were
expressed relative to those in the untreated control culture.
doi:10.1371/journal.pone.0078979.g001
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(Fig. 3A) disclosed that both the MEK inhibitor U0126 and the
RSK inhibitor BI-D1870 reduced p-S6(S235), p-eIF4B, and
Lamc2 and MYC levels. U0126 reduced p-ERK levels but BI-
D1870 did not, demonstrating their target specificities. P-eIF4B
levels always correlated closely with Lamc2 and MYC levels, in
agreement with our previous study [21]. The mTORC1 inhibitor
rapamycin and the mTORC1/mTORC2 inhibitor Ku-0063794
greatly reduced p-S6(S240) and p-S6(S235) levels but had
essentially no effect on levels of p-ERK, p-RSK, p-eIF4B, or of
Lamc2 and MYC. Importantly, the rapamycin result confirmed
that eIF4B phosphorylation is accomplished by RSK without
requiring mTORC1-dependent S6K1 activity.
The oral SCC and dysplasia specimens and the SCC-68 and
POE9n cell lines we analyzed above were non HPV-related.
However, we have reported recently that high-risk HPV-related
vulvar epidermal dysplasias and SCCs contain regions positive for
Figure 2. Coincidence of p-S6(S235) and p-S6(S240) detectable in human oral dysplastic lesions and SCCs in vivo. Sections of normal
(A) and dysplastic (B-C) epithelium, and invasive SCC (D), stained with H&E and immunostained for Lamc2, p-S6(S240) and p-S6(S235). Scale bar:
200 mm. Enlarged insets of some regions are shown for easier viewing of p-S6 staining patterns. Panel A shows a region of Case 2, panel B of case 8,
panel C of case 7, and panel D of case 4 as described in Table 1. Note that normal epithelium did not express Lamc2 and neither S6 phosphorylation
event was detectable in the basal cells. Cells in dysplasias and SCCs always showed coincidence of the two S6 phosphorylation events. Dysplasias
varied with respect to frequency and intensity of Lamc2 expression and S6 phosphorylation, with Lamc2 cells representing a subset of p-S6 positive
basal cells and invasive SCCs contained many Lamc2 and basal layer p-S6 positive regions.
doi:10.1371/journal.pone.0078979.g002
Table 1. Human oral epithelial lesions examined for increased p-S6 and Laminin c2 by immunohistochemical staining.
Case # Histopathologic description % p-S6(S235)+ and p-S6(S240)+ % Lamc2+ Associated SCC?
1 dysplasia 23 10 yes
2 dysplasia 71 6 no
3 dysplasia 90 37 no
4 severe dysplasia 60 n.d. yes
5 severe dysplasia 44 33 yes
6 severe dysplasia 69 14 no
7 dysplasia 100 67 yes
8 slight atypia 0 0 no
9 severe dysplasia 34 12 no
10 severe dysplasia 83 83 no
Formalin-fixed, paraffin-embedded specimens of oral lesions were immunostained for p-S6(S235), p-S6(S240), and Lamc2 and the percentage of the total dysplasia
positive in the basal cell layer for these markers determined as described in Methods. Basal layer p-S6(235) and p-S6(240) immunostaining always corresponded
precisely. n.d.: not determined.
doi:10.1371/journal.pone.0078979.t001
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basal layer p-S6(S235) and Lamc2 [43]. Our earlier study found
that an activity of the E6 oncoprotein of HPV16 separate from its
ability to target p53 for degradation (disclosed by the E6 mutant
E6(JH26)) can instigate Lamc2 overexpression in keratinocytes
[21]. That study followed an earlier one by others reporting that
E6 activates mTOR in keratinocytes [44]. We therefore examined
confluent cultures of normal primary keratinocytes stably
engineered to express E6(JH26) for the activation status of
mediators of the EGFR/MAPK and mTOR pathways and for
effects of kinase inhibitors on Lamc2 and MYC expression. Both
gefitinib and U0126 reduced Lamc2 and MYC expression in N/
E6(JH26) cells, associated with greatly reduced p-ERK, p-RSK, p-
S6(S235), and p-eIF4B levels (Fig. 3A). BI-D1870 reduced p-eIF4B
levels and Lamc2 and MYC expression. As was the case for SCC-
68 and POE9n, the mTOR inhibitors Ku-0063794 and rapamy-
cin had little or no effect on Lamc2 or MYC expression or on p-
ERK, p-RSK, or p-eIF4B levels, while blocking the S6K1-
dependent S6(S240) phosphorylation and the S6(S235) phosphor-
ylation (Fig. 3A), the latter requiring prior S240 phosphorylation.
These results indicate that MAPK and mTOR signaling are
hyperactive in non HPV-related SCC and premalignant dysplastic
cells and that the E6 viral oncoprotein also activates these
pathways, independent of its p53 targeting function. Furthermore,
in all cases RSK activity is required for eIF4B phosphorylation and
correlates with Lamc2 and MYC overexpression.
If eIF4B activation is required for Lamc2 overexpression, then
the 59-UTR sequence of Lamc2 mRNA should confer depen-
dence for translation on the eIF4B activator RSK. To determine
this, we modified the bicistronic Renilla and Firefly luciferase
reporter plasmid pDL-N to insert the 59-UTR of Lamc2 upstream
of the Renilla luciferase coding sequence. We tested this reporter
in SCC-13 cells, comparing its expression with that of a pDL-N
construct containing the 59-UTR of ODC, the mRNA of which is
known to be eIF4B-dependent for translation [26], and with the
pDL-N control. The relative reporter activities of the constructs
containing the Lamc2 or ODC 59-UTR were reduced ,50% by
the RSK inhibitor BI-D1870 relative to controls (Fig. 3B).
Consistent with our Western blot analyses of neoplastic epithelial
cells above, the mTOR/S6K1 inhibitor Ku-0063794 had no
inhibitory effect on expression of the Lamc2 or ODC 59-UTR
reporter constructs (Fig. 3B).
eIF4B Laminin c2 translation requires active eIF4B
because of the 59-UTR sequence of its mRNA
EIF4B interacts with and potentiates the activity of eIF4A, an
RNA helicase that unwinds secondary structures in the 59-UTRs
of certain mRNAs to expose the AUG translation initiation site
[22,24,45]. We previously noted that the 59-UTR of Lamc2
mRNA is long (314 bases), GC-rich (63.4%), and energy favored
for stable stem-loop formation (energy/base 20.46 kcal/mol)
[21], similar to these features of the 59-UTRs of MYC and ODC.
We therefore sought to test the hypothesis that Lamc2 expression
is dependent upon eIF4B by testing the effects of shRNA-mediated
eIF4B knockdown.
We transduced POE9n and SCC-68 cells to express either a
control shLuciferase or three different shEIF4Bs and 4d later
determined the effects on eIF4B mRNA levels (Fig. 4A). eIF4B
shRNA clones #1 and #4 resulted in the greatest eIF4B mRNA
knockdown, from 50–80%. As expected, the levels of Lamc2 and
MYC mRNAs were not affected (Fig. 4A), consistent with eIF4B
Figure 3. MAPK/RSK-dependent, mTOR/S6K1-independent activation of eIF4B and Lamc2 mRNA translation. A) Western blot analysis
of confluent cultures of SCC-68, the premalignant oral keratinocyte line POE9n, and normal primary keratinocyte strain N engineered to express the
JH26 mutant of HPV16 E6 (N/E6(JH26). Cultures were treated for 24 hr with the indicated kinase inhibitors and then analyzed for levels of Lamc2 and
MYC protein and for the phosphorylated, activated forms of signaling proteins and translation factors. The Lamc2 band shown is the 155 kD
intracellular form and not the 105 kD form that predominates after secretion and proteolytic processing. The bar graphs below show densitometric
analysis of Lamc2 and p-EIF4B levels in each drug treatment condition relative to untreated control cultures of each line, as described in panel B. B)
SCC-13 cells transfected with the reporter constructs pDL-N, pDL-N/(Lamc2 59-UTR), and pDL-N/(ODC 5-9UTR) with or without the RSK inhibitor BI-
D1870 or the mTORC1/2 inhibitor Ku-0063794 and analyzed for Renilla and Firefly luciferase activity. Reduction caused by BI-D1780 in Lamc2 59UTR-
and ODC 59UTR-dependent expression had P values for significance of 0.0043 and 0.01, respectively.
doi:10.1371/journal.pone.0078979.g003
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regulating Lamc2 and MYC expression at the level of translation
and not transcription. To determine the ability of sh.eIF4B to
reduce eIF4B protein levels, its time-course, and its consequence
for Lamc2 and MYC protein expression, we transduced SCC cells
with the most potent eIF4B shRNA (clone #1) and analyzed cells
1, 2 and 3 d later by Western blotting. EIF4B protein levels were
substantially reduced by 2 d and reduced further 3 d after
transduction (Fig. 4B). Levels of the short half-life MYC protein
were greatly reduced by 2 d, whereas Lamc2 levels were
substantially reduced by 3 d after transduction (Fig. 4B).
We next engineered premalignant (POE9n) keratinocytes and
SCC cells (SCC-13 and SCC-68) to express eIF4B shRNA and
analyzed them by Western blotting at 4 d post-transduction. As
expected from the qPCR and Western blot results (Fig. 4A,B),
both eIF4B shRNA clones #1 and #4 yielded highly efficient
reduction of eIF4B protein and consequently of p-eIF4B levels
(Fig. 4C). Clones #1 and #4 also reduced MYC and Lamc2
protein levels, firmly demonstrating that eIF4B is essential for
Lamc2 and MYC protein expression. Western blotting for Lamb3
and ERK showed eIF4B knockdown had specific effects on Lamc2
and MYC and did not result from general translation inhibition
(Fig. 4C).
Discussion
Understanding the molecular mechanisms underlying neopla-
sia-associated biomarkers, such as Lamc2 and p-S6(235), is very
important for achieving earlier and more reliable detection of
premalignancy as well as identifying targets for small molecule
anti-cancer therapeutics. Here we have elucidated the mechanism
underlying MAPK-dependent Lamc2 overexpression, a biomark-
er that appears in regions of many dysplastic epithelial lesions and
persists in invasive SCC. Interestingly, expression of the growth-
promoting transcription factor and oncogene MYC is regulated in
parallel with Lamc2 by the RSK/eIF4B-dependent mechanism
Figure 4. The eIF4B requirement for Lamc2 and MYC protein expression demonstrated by shRNA knockdown. A) Effect of eIF4B
knockdown on eIF4B, Lamc2, and MYC mRNA levels. RNA from POE9n and SCC-68 cells transduced to express shRNAs targeting eIF4B or Luciferase
was analyzed by qPCR for eIF4B, Lamc2, and MYC transcripts. Results of each cell line was internally normalized to GAPDH mRNA levels and expressed
relative to that of cells transduced to express shLuciferase, set at an arbitrary value of 1. B) Western blot analysis of the time-course of eIF4B protein
reduction in SCC cells transduced to express shRNA.eIF4B#1 and examined 1, 2, and 3 d after transduction. C) Western blot analysis of the
premalignant cell line (POE9n) and two SCC lines (SCC-13, SCC-68) transduced with three shRNA vectors targeting EIF4B and a control shRNA vector
targeting luciferase.
doi:10.1371/journal.pone.0078979.g004
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that enables translation of mRNAs with long, highly structured
59UTRs.
The premalignant dysplastic cell line POE9n and the SCC lines
SCC-68 and SCC-13 we studied here do not contain integrated
HPV genomic DNA. An alternate pathway of transformation in
stratified squamous epithelia involves HPV16/18 infection,
genomic integration, and consequent expression of the E6 and
E7 viral oncoproteins as an early step [46]. Although rare in oral
cavity dysplasia and SCC, high risk HPV accounts for a large
proportion of vulvar dysplasias and SCC and we have found that
basal p-S6(235) and Lamc2 immunostaining in such lesions is
similar to that of non HPV-related oral and vulvar lesions [21,43].
Our present study has found that a function of HPV16E6 separate
from its ability to render cells p53-deficient activates the MAPK/
RSK/eIF4B pathway to cause Lamc2 and MYC overexpression.
Our study confirmed an earlier report [44] that described E6
activation of mTOR/S6K1, but we found that activation of this
pathway is not essential for Lamc2 and MYC overexpression.
We noted previously [21] that the Lamc2 mRNA contains
upstream of the translation initiation site a 314 bp sequence
predicted to form a highly stem-looped structure that would
require unraveling by the eIF4B-dependent eIF4A helicase. Here
we have found by sh.eIF4B knockdown experiments in SCC cells
that this translation factor is essential for Lamc2 protein synthesis
and also (as expected from previous studies [26]) for MYC protein
synthesis. Furthermore, our reporter analysis showed that the 59-
UTR sequence of Lamc2 confers upon its mRNA RSK-
dependence for translation into protein.
The experiments described here have identified phosphoryla-
tion of ribosomal protein S6 at its S240 and S235 residues as
specific readouts of mTOR hyperactivity vs. combined mTOR
and MAPK hyperactivity, respectively. Early test tube studies
using purified rat S6K1 and ribosomes concluded that S6K1 can
phosphorylate both sites on S6 [47]. Subsequent studies in cells
[48,49] found that RSK is primarily responsible for S6(S235)
phosphorylation and perusal of the data in these reports suggested
to us that S235 phosphorylation is dependent upon or greatly
enhanced by prior S240 phosphorylation by S6K1. Our results
establish clearly that in premalignant keratinocytes and SCC cells
S6(S235) phosphorylation is accomplished exclusively by RSK and
requires prior phosphorylation of S240 by S6K1. In vivo, activation
of both pathways, detectable immunohistochemically with anti-
bodies specific for these two S6 phosphorylation sites, appears to
occur at the same time during neoplastic progression, consistent
with a single event being responsible for activating both pathways.
The common step could be mitogen binding to and activation of
EGFR, which activates the MAPK and PI3K and pathways [50].
On the other hand, our study found that a PI3K inhibitor did not
reduce S6(S240) phosphorylation in culture, even while greatly
reducing AKT phosphorylation. Thus, mTOR/S6K1 activity is
independent of PI3K in our culture system, as expected for cells
that are not subject to nutrient or growth factor limitation [51].
The use of p-S6(S240) and p-S6(S235) as immunohistochemical
biomarkers for mTOR/S6K1 and MAPK/RSK pathway activa-
tion has potential application in analyzing epithelial lesions for
potential premalignant change. These antigens are abundant and
well-preserved in the basal, proliferative cell populations of
dysplasias and tumors, unlike other phosphoproteins such as p-
eIF4B in the MAPK pathway and p-eIF4E in the mTOR pathway
[21].
Lamc2 overexpression is a rather early event in dysplastic,
noninvasive lesions that may progress to SCC [19]. As shown here
and in our recent studies, Lamc2 overexpression always occurs in
vivo in cells that have increased levels of p-S6(S235) and p-S6(S240)
[21,43]. p-S6 immunostaining in the basal cell layer of dysplasias
also shows promise as a potential biomarker heralding more
probable future progression to invasive SCC. Some p-S6 positive
regions of dysplastic lesions do not overexpress Lamc2. Concom-
itant Lamc2 staining may indicate higher and more sustained
MAPK pathway hyperactivity, which may signify a greater risk of
progression. Prospective studies of serial biopsies taken from the
same patient, immunostaining for p-S6(S235) and Lamc2, will be
necessary to test the hypothesis that one or both of these
biomarkers of MAPK/RSK activation predicts future progression
to invasive SCC. Our results also support studies to determine the
effectiveness of small molecule inhibitors of eIF4B, or of the eIF4A
helicase it activates, to treat SCCs or to shrink or ablate potentially
premalignant lesions, especially considering that translation of the
growth-inducing transcription factor MYC is also eIF4B/eIF4A-
dependent. Several natural and synthetic eIF4A inhibitors have
been identified and are being studied for their specificity, toxicity,
and potential activity as anti-cancer agents [52-54].
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